Biomedical Innovation Articles

The EU Research and Innovation Programme 2021-2027 has gathered a lot of attention from the research communities around Europe this time around with their Cluster Health topics that are open for proposals. The published destinations aim to address acute and long-term problems in the healthcare ecosystem and the health and well-being of citizens from a societal point of view – without forgetting the lessons learned from the Covid-19 pandemic.

For 2021 inXso has created a webinar series outlining some specific features that are essential for global design of medical technology, and introduces some regulatory aspects in context of EU MDR and Swiss regulatory landscape, as well as some basic features from Chinese and Japanese regulations that everyone – or every company – considering these healthcare markets should now of.

The life science industry distinguishes itself from other high-technology industries with such fundamental dimensions as applying scientific knowledge to provide technological solutions aiming to improve health care and quality of life – in a highly regulated environment. At the same time, usually purchasing decisions are not made by end-consumers, but their physicians or such third party as an insurance company, for example.